National Action Plan for Rare Diseases in Austria

1:1
Austria’s national strategy defining priority areas and concrete measures to improve care, research, and access to services for people living with rare diseases.

This publication presents Austria’s National Action Plan for Rare Diseases (NAP.se), developed on behalf of the Federal Ministry of Health. It defines nine strategic action areas covering governance, diagnosis, clinical care, research, information systems, patient involvement, and access to therapies, including objectives, proposed measures, responsible stakeholders, and indicative timelines. The publication is available in German only.

Acces this publication
Nationale Aktionsplan für seltene Erkrankungen

Year of publication

2015

ISBN

978-3-85010-538-5

Source

Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (Austria), Austrian Public Health Institute (Gesundheit Österreich GmbH – GÖG), National Coordination Centre for Rare Diseases (NKSE)

Author

Florian Bachner; Margit Gombocz; Claudia Habl; Joy Ladurner; Christine Leopold; Ursula Unterberger; Till Voigtländer

You might also be interested in

How National Mirror Groups strengthen rare disease research and policy alignment in Europe

How National Mirror Groups strengthen rare disease research and policy alignment in Europe

By connecting national priorities with European initiatives, NMGs support stronger coordination, knowledge exchange and alignment across the rare disease ecosystem.
Conference "Advancement of Treatments for Rare Diseases" in Cyprus, June 2026

Cyprus conference connects European research priorities with the path to rare disease treatments

At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.
State of the art rare disease country reports ERDERA 2025

State of the art 2025 rare disease country report: Sweden

This 2025 country report outlines the policy, research, care and support landscape for rare diseases in Sweden.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Call Text

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.

ERDERA's

search form